Partnerships: Bargaining Biotechs

Gopal,Kevin;

Article

Pharmaceutical Executive

April 1, 2001

Pharmaceutical Executive

Pharmaceutical Executive-04-01-2001

Volume0

Issue 0

Partnerships: Bargaining Biotechs

Author(s):

Kevin Gopal

Uniondale, New York, USA-Thirty-eight companies submitted proposals to develop OSI-774, OSI Pharmaceuticals' lead cancer candidate, making it the most sought-after compound of 2000. The statistic was revealed with some satisfaction by Myrtle Potter, chief operating officer of Genentech, the joint winner-along with Roche, its majority stockholder-at the Economist Conferences' annual pharmaceuticals conference.

Articles in this issue

Internet DTC - Minding Your P's & Q's

Regulation: Two-Track Plan

Policy: Tectonic Shift

Liberated?

A Matter of Taste

Partnerships: Bargaining Biotechs

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Partnerships: Bargaining Biotechs

Newsletter